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Abstract
Background: This study was designed to investigate EGFR protein expression, EGFR copy number and EGFR
mutations in lung adenocarcinomas, to explore the relationship of the three markers.
Methods: EGFR status was analyzed in surgically resected lung adenocarcinoma samples from 133 Chinese
patients by three methods: protein expression (n = 133) by standardized immunohistochemistry (IHC), gene copy
number (n = 133) by fluorescence in situ hybridization (FISH), and mutation analysis using the Scorpion
amplification refractory mutation system (ARMS) (n = 133).
Results: The results showed that 68.4% of the samples were positive by IHC, 42.1% were positive by FISH, and
63.9% contained activating kinase domain mutations. EGFR mutations were more frequent in non-smoking patients
(p = 0.008), and EGFR mutations were associated with EGFR FISH positivity (p < 0.0001). When using 10% positivity
and 2+ as cutoffs, EGFR protein expression was significantly correlated with EGFR FISH positivity (p = 0.012) and
EGFR mutations (p = 0.008) after Bonferroni correction.
Conclusion: EGFR protein expression, EGFR copy number and EGFR mutations were closely related to each other.
Standard methods and interpretation criteria need to be established.
Background
Lung cancer is one of the leading causes of cancer-related
deaths in the world. Recently, EGFR-targeted therapy has
proven effective in treating non-small cell lung cancer
(NSCLC). The epidermal growth factor receptor (EGFR,
HER-1/ErbB1) is a receptor tyrosine kinase (TK) of the
ErbB family, which consists of four closely related recep-
tors: HER-1/ErbB1, HER-2/neu/ErbB2, HER-3/ErbB3,
and HER-4/ErbB4. The agents approved for the treat-
ment of NSCLC are monoclonal antibodies (MoAbs)
directed against EGFR and small-molecule TK inhibitors
(TKIs). Given the low response rate, the identification of
the patients who are most likely to derive clinical benefit
from EGFR-targeted therapy is important [1-6].
Increased EGFR gene copy number as detected by
FISH was strongly correlated with response, progression-
free survival (PFS) and overall survival (OS) after treat-
ment with EGFR TK inhibitors (TKI) in previous studies.
These results suggested that a high EGFR gene copy
number is a strong indicator of TKI sensitivity [7,8].
Several clinical features were found to be associated
with increased response rates to EGFR TKIs, including
Asian ethnicity, non-smoking history, female gender and
adenocarcinoma histology. EGFR mutations were
reported to be associated with these clinical features in
several clinical trials [9]. Mutations in the tyrosine
kinase domain of EGFR were reported in the majority of
tumors with dramatic responses to EGFR-targeted
therapies, and an activating mutation of the EGFR tyro-
sine kinase domains was shown to be associated with
EGFR TKI sensitivity [10-12]. EGFR gene mutations
predicted increased overalls u r v i v a lo fT K I - t r e a t e d
patients in some studies, but failed to indicate a survival
benefit in other series of studies [10-14]. In recent stu-
dies, an association between EGFR mutations and high
EGFR copy number was demonstrated [7,15].
It is still not clear whether EGFR protein expression
could be a predictor of successful EGFR-targeted therapy.
Due to the different antibodies, protocols and interpreta-
tion criteria used, as well as the different patient popula-
tions analyzed, EGFR proteine x p r e s s i o ni nN S C L Ch a s
been variably reported. The association between EGFR
protein expression as detected by immunohistochemistry
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The reported relationship between EGFR protein expres-
sion and EGFR copy number/EGFR mutation also varies
in different studies [16,17].
Multiple methodological approaches have been used,
including mutational analysis, fluorescence in situ hybri-
dization, and immunohistochemistry. Conflicting results
reflect the lack of standardization of the methodology
and interpretation. In this study, we used the standar-
dized PharmDx (Dako) IHC kit to analyze EGFR expres-
s i o n .W ea l s oa n a l y z e dg e n ec o p yn u m b e rb yF I S H
using the most standard probes (Vysis), and the muta-
tions were analyzed by the stable and sensitive Scorpion
amplification refractory mutation system (ARMS). We
attempted to explore the relationship between EGFR
protein expression, EGFR copy number, and EGFR
mutation.
Methods
Patients
All of the specimens were selected by two pathologists,
only patients with primary lung adenocarcinoma were
selected, intrapulmonary metastases and recurrent dis-
ease were not included in this study. None of the
selected patients were previously treated with che-
motherapy, radiation or anti-EGFR therapy. Only cases
with available EGFR immunohistochemistry, mutational
status, and EGFR FISH data were analyzed. Clinical
information included gender, age, smoking status, tumor
stage and lymph node metastasis status. One hundred
and thirty-three Chinese patients with lung adenocarci-
nomas were selected from 886 lung cancer patients who
underwent surgery at the Department of Surgery, Peking
Union Medical College Hospital from Jan. 2000 to Jan.
2008. The patient group consisted of 62 males and 71
females, with an average age of 60 years. Cancer staging
was classified according to the TNM cancer staging sys-
tem of the American Joint Committee of Cancer (13):
stage I, 69 cases; stage II, 17 cases; stage III, 33 cases
and stage IV, 14 cases. The World Health Organization
Classification of Tumors was used for histological classi-
fication and grading (18). The institutional review board
at the Peking Union Medical College Hospital approved
this study, and informed consent was obtained from all
patients.
Sample preparation
All specimens were fixed in 10% buffered formalin and
embedded in paraffin according to standard procedures.
All the tissues were fixed immediately after surgical
resection, time from tissue acquisition to fixation was as
short as possible; samples were fixed in 10% neutral buf-
fered formalin (avoiding Bouin or any fixative containing
heavy metal ions) for 6-48 hours; samples were sliced
properly after appropriate gross inspection and margins
designation and placed in sufficient volume of 10%
neutral buffered formalin.
Serial sections (4-5 μm thickness) placed on positively
charged slides (MENZEL-GLASSER, GERMAN) were
used for hematoxylin and eosin staining, immunohisto-
chemistry, and FISH detection of EGFR.
FISH analysis of EGFR copy number
EGFR FISH analysis was carried out using the LSI EGFR
SpectrumOrange/CEP 7 SpectrumGreen probe (Vysis,
Abbott Laboratories) according to the manufacturer’s
protocol. Sections were incubated at 56°C overnight,
deparaffinized by washing in CitriSolv (Fisher Scientific,
Pittsburgh, PA), and dehydrated in 100% ethanol. After
incubation in 2× saline sodium citrate buffer (2× SSC,
pH 7.0) at 75°C for 15-25 minutes, sections were digested
with proteinase K (0.25 mg/mL in 2× SSC; pH 7.0) at
37°C for 15-25 minutes, rinsed in 2× SSC at room tem-
perature for 5 minutes, and dehydrated in a series of
increasing concentrations of ethanol (70%, 85%, and
100%). The EGFR/CEP 7 probe set was applied to the
selected area based on the presence of tumor foci on
each slide, and the hybridization area was covered with a
glass coverslip and sealed with nail polish. The slides
were incubated at 80°C for 8-10 minutes for co-denatura-
tion of the chromosomal and probe DNA and were then
hybridized at 37°C for 20-24 hours. Post-hybridization
washes were performed in 1.5 M urea and 0.1× SSC
(pH 7.0 - 7.5) at 45°C for 30 minutes, and in 2× SSC
for 2 minutes at room temperature. After the samples
were dehydrated in ethanol as above, 4′,6 ′-diamidino-2-
phenylindole (DAPI) in phosphate-buffered saline and
glycerol (Vysis) was applied for chromatin counterstain-
ing. FISH analyses were performed independently by two
authors who were blinded to the clinical characteristics
of the patients and to all other molecular variables. For
EGFR FISH analyses, 60 nuclei were scored for signals
from both DNA probes using an Olympus BX51TRF
microscope (Olympus, Japan) equipped with a triple-pass
filter (DAPI/Green/Orange; Vysis) at a final magnifica-
tion of 1000×.
Chromosome 7 polysomy and monosomy were defined
as the presence of ≥ three signals and one signal, respec-
tively, in more than 20% of the tumor cells. EGFR gene
status was classified into six categories according to the
frequency of tumor cells with specific copy numbers of
t h eE G F Rg e n ea n dt h ec h r o m o s o m e7c e n t r o m e r ea s
described elsewhere [7]: disomy (≤ 2c o p i e si n≥ 90% of
cells), low trisomy (≤ 2c o p i e si n≥ 40% of cells, 3 copies
in 10 - 40% of cells, and ≥ 4 copies in < 10% of cells),
high trisomy (≤ 2c o p i e si n≥ 40% of cells, 3 copies in
≥ 40% of cells, and ≥ 4 copies in < 10% of cells), low
polysomy (≥ 4 copies in 10 - 40% of cells), high polysomy
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(a: presence of tight EGFR gene clusters(≥4s p o t s )i n
≥10% tumor cells;b: a ratio of the EGFR gene to chromo-
some 7 of ≥ 2, c: ≥ 15 copies of EGFR per cell in ≥ 10%
of cells). Based on the EGFR gene status, patients were
further classified into two groups: 1) EGFR FISH-negative
or low gene copy (disomy, low trisomy, high trisomy, and
low polysomy) and 2) EGFR FISH-positive or high gene
copy (high polysomy and gene amplification)[18]. For
each FISH preparation, known positive and negative cells
were used as controls.
Scorpion ARMS analysis of EGFR mutations
The tumor specimens were fixed with 10% neutral buf-
fered formalin and embedded in paraffin. Using a
NucleoSpin tissue isolation kit (Machery-Nagel, Ger-
many), DNA was extracted from tumor tissues derived
by manual microdissection carried out to enrich tumor
cells. EGFR mutations of exon 18-21 were detected
u s i n gt h eD x SA R M SE G F R 2 9m u t a t i o nt e s tk i t( D x S
Limited, Manchester, UK). Twenty-nine of the most
common somatic mutations of the EGFR gene can be
detected by the kit.
Immunohistochemical analysis of EGFR expression
Immunohistochemistry for EGFR was performed using
the EGFR pharmDx kit (DakoCytomation, Denmark)
according to the manufacturer’s instructions. Antibody
binding was visualized using the EnVison detection kit
(DakoCytomation, Denmark).
Immunohistochemical staining for EGFR was scored
as follows: 0, no discernible staining or presence of
background staining only; 1+, equivocal discontinuous
membrane staining; 2+, unequivocal membrane staining
with moderate intensity; and 3+, strong and complete
plasma membrane staining. More than 10% of the cells
were required to meet the criteria for EGFR analysis.
Samples with more than 10% of the tumor cells showing
membranous (partial or complete) staining at the 2+
and 3+ staining levels were considered to be EGFR
IHC-positive, and the highest score obtained among dif-
ferent areas of the same tumor was used as the final
EGFR IHC result for that tumor. To determine which
criteria were more suitable, two other evaluation criteria
were used in this study. The first was that samples with
more than 10% of tumor cells showing membranous
(partial or complete) staining of any intensity were con-
sidered to be EGFR IHC-positive. The second criterion
we used was the semiquantitation score defined by
Capuzzo et al. [7], with the modification that we evalu-
ated membranous staining and determined four levels of
intensity (0, 1+, 2+ and 3+) according to the instruc-
tions of the manufacturer (Dako). The IHC score was
calculated by multiplying the staining intensity and the
fraction of positive cells (0-100%). The scores were
0-300 in different tumors, and scores of more than 100
were considered as indicative of EGFR IHC positivity
[19,20].
Statistical analysis
Statistical analyses were performed using Pearson’s
C h i - s q u a r e dt e s to rF i s h e r ’s exact test to determine
significant clinicopathological differences between EGFR
expression in positive and negative tumors, between
EGFR FISH-positive and FISH-negative tumors, and
between tumors with and without EGFR mutations.
These tests were also used to determine the association
between EGFR protein expression, EGFR FISH results,
and EGFR mutations. Bonferroni correction was per-
formed to adjust for multiple comparisons, differences
with P < 0.05/comparison times were considered
significant.
Results
EGFR copy number in lung adenocarcinomas
Eleven (8.3%) of the 133 cases showed EGFR amplifica-
tion, 45 cases (33.8%) showed high polysomy, 38 cases
(28.6%) showed low polysomy, 1 (0.7%) case showed high
trisomy, 15 cases (11.3%) showed low trisomy, and
23 cases (17.3%) showed disomy. Fifty-six cases (42.1%)
showed FISH positivity according to the criteria of
Capuzzo et al[7]. After Bonferroni correction for 5 com-
parisons, P < 0.01 were considered significant, EGFR FISH
positivity was not associated with gender, smoking status,
age, lymph node metastasis or tumor stage (P ≥ 0.01)
(Table 1).
EGFR mutations in lung adenocarcinomas
Eighty-five (63.9%) of the 133 cases showed EGFR muta-
tions, which included 2 exon 18 G719X mutations (one
also had an exon 20 S768I mutation), 39 exon 19 dele-
tions, 4 exon 20 insertion mutations, 3 exon 20 S768I
mutations (one also had an exon 18 G719X mutation),
35 exon 21 L858R mutations (one also had an exon
20 T790 M mutations), and 3 exon 21 L861Q mutation.
After Bonferroni correction for 5 comparisons, P < 0.01
were considered significant, EGFR mutations were signif-
icantly associated with smoking status (non-smoking vs.
smoking, p = 0.008), and were not associated with age,
gender, lymph node metastasis or tumor stage (p ≥ 0.01)
(Table 1).
Association between EGFR copy number and EGFR
mutations
In our results, EGFR FISH positivity was significantly
associated with EGFR mutations (p < 0.001). Forty-five
of the 56 (80.4%) FISH-positive cases, which included 7
amplifications and 38 instances of high polysomy
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negative cases, which included 23 low polysomy cases,
10 low trisomy cases, and 7 disomy cases showed EGFR
mutations. There were no significant differences in the
EGFR FISH-positive rate among different mutation pat-
terns (p ≥ 0.05) (Table 2).
EGFR protein expression in lung adenocarcinomas
Sixty-one (45.8%) of the 133 cases showed EGFR expres-
sion levels corresponding to 3+, 30 (22.6%) cases showed
EGFR levels of 2+, and 23 (17.3%) cases showed EGFR
levels of 1+; the remaining 19 (14.3%) cases showed level
0 staining (n = 133 lung adenocarcinoma samples).
Correlation of EGFR expression, EGFR copy number and
EGFR mutations
According to the criteria that samples with more than
10% of tumor cells showing membranous staining of any
intensity should be considered as EGFR IHC-positive,
114 cases were IHC-positive and 19 cases were IHC-
negative. After Bonferroni correction for 2 comparisons,
P < 0.025 were considered significant, the FISH-positive
rate was not significantly different between IHC-positive
and IHC-negative groups (p = 0.132), and the mutation
rate was not significantly different between the IHC-posi-
tive and IHC-negative groups (p = 0.105) (Table 3).
According to the criterion that samples with more than
10% of tumor cells showing membranous staining at levels
2+ and 3+ should be considered to be EGFR IHC-positive,
91 cases were IHC-positive and 42 cases were negative.
After Bonferroni correction for 2 comparisons, P < 0.025
were considered significant, the FISH-positive rate was sig-
nificantly higher in the IHC-positive group than in the
IHC-negative group (p = 0.012), and the mutation rate
was significantly higher in the IHC-positive group than in
t h eI H C - n e g a t i v eg r o u p( p=0 . 0 0 8 )( F i g u r e1 ,T a b l e3 ) .
But the patients positive for the three EGFR markers did
not completely overlap; some of FISH-positive and mutant
samples was IHC-negative (Figure 2).
According to semiquantitation criteria, 88 cases were
IHC-positive and 46 cases were negative. After Bonfer-
roni correction for 2 comparisons, P < 0.025 were con-
sidered significant, the mutation rate was significantly
higher in the IHC-positive group than in the IHC-nega-
tive group (p = 0.008), the FISH-positive rate was higher
in the IHC-positive group than in the IHC-negative
group (approached significance, p = 0.027) (Table 3).
Similar results were obtained using either of the latter
two criteria. The results indicated that EGFR IHC positiv-
ity was significantly correlated with EGFR mutations and
EGFR FISH positivity (the association between the third
EGFR IHC criteria and EGFR FISH positivity was close to
statistically significant). Due to its easier application, we
used the criterion that samples with more than 10% of
tumor cells showing membranous staining at levels 2+
and 3+ should be considered to be EGFR IHC-positive in
our following analysis. There were no significant differ-
ences in the rates of IHC positivity in patients of different
age, gender, smoking status, lymph node metastasis and
stage (p ≥ 0.01 after Bonferroni correction).
Discussion
Due to the potential high benefit of EGFR TKI therapy
for treatment of lung adenocarcinomas, several clinically
trials have focused on lung adenocarcinomas. Because a
low proportion (<30%) of patients respond to EGFR TKI,
patient selection is very important for initiating EGFR
TKI therapy [1-6]. EGFR gene copy number determined
by FISH, protein expression determined by IHC and
EGFR tyrosine kinase mutations are all potential markers
to be used as selection criteria in EGFR-targeted therapy.
Multiple methodological approaches have been used in
Table 2 Relationship between EGFR copy number and
mutation
Mutation FISH
Positive Negative
Positive 45 40
negative 11 37
P value P < 0.0001
Table 1 Relationship between EGFR mutation, EGFR copy
number and clinicopathological characteristics of lung
adenocarcinoma
IHC Mutation FISH
+- P
value
+- P
value
+- P
value
Gender
Male 41 21 0.595 34 28 0.042 27 35 0.753
Female 50 21 51 20 29 42
Age
>60 50 23 0.984 51 22 0.115 30 43 0.795
<60 41 19 34 26 26 34
Smoking status
Positive 61 25 0.400 62 24 0.008 36 20 0.938
Negative 30 17 23 24 50 27
Lymph node
metastasis
Positive 59 28 0.836 58 29 0.363 33 54 0.180
Negative 32 14 27 19 23 23
Stage
I 47 22 0.937 45 24 0.744 22 47 0.021
II 15 2 12 5 11 6
III 21 12 19 14 14 19
I V 86 9 5 86
After Bonferroni correction, P < 0.01 was considered as significant, only the
association between EGFR mutation and smoking status was statistically
significant.
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and EGFR protein expression, but the results were con-
tradictory. It is important to standardize the approach
and decide which assays are best to predict patient
responses to targeted therapies.
It was demonstrated that mutations in exons 18 to 21
of the tyrosine kinase domain of EGFR were correlated
with a high response to EGFR TKIs in lung adenocarci-
nomas. In previous studies, EGFR mutations were
reported in about 22% to 67%, 10% to 24%, and 3% to
25% of Asian population, Southern European, and Amer-
ican populations with lung adenocarcinomas
[10,12,14,15,21-26]. In this study, 63.9% (85/133) of
patients with lung adenocarcinomas had EGFR muta-
tions. The higher frequency of mutations can most likely
be attributed to the sampling from a Chinese population
and the sensitive Scorpion ARMS method used.
Although direct sequencing is still the gold standard
method for mutation screening, many more sensitive
methods have been developed, and Scorpion ARMS has
been used in several clinical trials. Scorpion ARMS can
detect a lower proportion of mutant alleles than direct
sequencing; we demonstrated that Scorpion ARMS was
more sensitive than direct sequencing in detecting EGFR
mutations in lung carcinomas in our previous study [27].
Others reported that some cases with mutations are
missed by direct sequencing of clinical tumor samples;
however, these cases could be detected by more sensitive
techniques. In this study, about 90% (74/85) of EGFR
mutations consisted of deletions in exon 19 and L858R
mutations in exon 21, and EGFR mutations were signifi-
cantly associated with smoking status, consistent with
previous reports, but not associated with gender, this
may be caused by small sample size in our group. Other
less common mutations were also identified in our study,
including one T790 M mutation that has been demon-
strated to result in EGFR TKI resistance in clinical trials.
High EGFR gene copy number/amplification has been
reported in 7% to 45% of lung carcinomas. This large
range may be due to variations in techniques, criteria
for determining positivity, and interobserver variability
[7,8,15,20,28]. In our study, standard Vysis EGFR FISH
probes and the Capuzzo et al. criteria were used to eval-
uate EGFR copy number in lung adenocarcinomas. We
found that 42.1% (56/133) of lung adenocarcinomas
showed EGFR FISH positivity, and that EGFR FISH
positivity was more frequent in late stages than in early
stages of lung adenocarcinomas (although no statisti-
cally significant difference showed after Bonferroni cor-
rection, but there was trend show difference, probably
due to the reason of low volume samples.). Awaya et al.
[29] detected FISH only in the invasive components of
adenocarcinomas, and Kim et al. [30] frequently
observed increased EGFR in advanced stages of lung
adenocarcinoma. This may be consistent with previous
reports of poor prognosis of lung carcinomas with
higher EGFR copy numbers. Our studies and several
others from Western and American populations demon-
strated that high EGFR copy numbers were significantly
associated with EGFR mutations, contrary to the result
published by Sasaki et al. [31] in a study of Japanese
patients in which no correlation was found between
EGFR copy number and EGFR mutation. There may be
reasons other than ethnicity for this discrepancy. The
relationship between high EGFR copy number and
EGFR mutation is complex. Recent studies report a
mutant allele specific imbalance of oncogenes in tumor
cells harboring gene mutation; copy number gain of
EGFR usually occurred in the cells with an EGFR muta-
tion[32]. Previous studies reported that EGFR mutant
alleles were amplified selectively, resulting in a high
EGFR copy number[15]. Yatabe, et al. [33] reported that
EGFR amplification was acquired during invasive
growth of lung adenocarcinoma with EGFR mutations.
Table 3 Relationship between EGFR protein expression and EGFR copy number, and mutation
IHC criteria Mutation FISH
positive negative P value positive negative P value
First criteria
Positive (>10% tumor cells, ++ and +++) 65 26 0.008 45 46 0.012
Negative 20 22 11 31
Second criteria
Positive (>10% tumor cells, any intensity) 76 38 0.105 51 63 0.132
Negative 9 10 5 14
Third criteria Positive (H Score ≥ 100) 62 24 0.008 42 44 0.027
Negative(H Score < 100) 23 24 14 33
After Bonferroni correction, P < 0.025 was considered as significant. For using the first IHC criteria, IHC were significantly associated with mutation and FISH. For
using the second IHC criteria, no significant association was found between IHC and mutation or FISH. For using the third IHC criteria, IHC was significantly
associated with mutation, approached significant associated with FISH(P = 0.027,close to 0.025)
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Page 5 of 9Figure 1 The consistency of three biomarkers. A-C: Case 1, three biomarkers were all positive in the same case, A: IHC positive(3+), B: FISH
positive (amplification), C: Curves for exon 19 using the Scorpions ARMS method, if only one ascending curve showed the wild-type, more than
two ascending curves showed the mutation. Two ascending curves in this case indicated mutation(the left curve represented wild type, the
right curve represented mutant, exon 19 deletion). D-F: Case 2, three biomarkers were all negative in the same case. D: IHC negative, E: FISH
negative(low trisomy), F: mutation negative(one ascending curve indicated EGFR wild type).
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copy number was a relatively late event in NSCLC
pathogenesis and that EGFR mutation preceded EGFR
amplification. These may partially explain the associa-
tion between high EGFR copy number and EGFR muta-
tion, the precise mechanism needs to be clarified in
future studies.
EGFR expression has been variably reported in 27 to
83% of NSCLC cases, and there are conflicting results
on the prognostic implication of EGFR expression in
NSCLC.
Different EGFR IHC results highly depend on the type
of antibody, procedure protocols, selection of scoring
methods, and cut-offs implemented. A standard method
has not been adopted, and the significance of EGFR
p r o t e i ne x p r e s s i o ni nN S C L Cr e m a i n sc o n t r a d i c t o r y
[35-39]. To select the best evaluation standard for EGFR
IHC, we compared three different criteria in our study.
When we used the criterion that samples with more than
10% of tumor cells showing membranous staining of
l e v e l so f2 +a n d3 +s h o u l db ec o n s i d e r e dt ob eE G F R
IHC-positive, the results were statistically similar to
those obtained using the Capuzzo et al[7] criteria. EGFR
protein expression was significantly associated with
EGFR copy number and EGFR mutations, and this was
consistent with results from most of the previous studies
[40]. In contrast, if we used 10% positivity regardless of
intensity as a cut-off, the results were quite different, and
no correlation was found between EGFR protein expres-
sion, EGFR copy number and EGFR gene mutation.
Figure 2 The inconsistency of three biomarkers. The three biomarkers were not completely overlap, some IHC positive or FISH positive
patients were mutation negative. A-C: Case 3, A: IHC positive(3+), B: FISH positive(amplification),C: mutation negative(one ascending curve
indicated EGFR wild type). D-F: Case 4, D: IHC positive(2+), E: FISH negative(disomy), F: Curves for exon 19 using the Scorpions ARMS method, if
only one ascending curve showed the wild-type, more than two ascending curves showed the mutation. Two curves in this case indicated
mutation(the left curve represented wild type, the right curve represented mutant, exon 19 deletion). G-I: Case 5, G: IHC negative, H: FISH
positive(high polysomy), I: Curves for exon 21 using the Scorpions ARMS method. Two ascending curves in this case indicated mutation (the left
curve represented wild type, the right curve represented mutant, exon 21 L858R mutation)
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dard methods and interpretation of standards is very
important in clinical practice.
We prefer to use 10% positivity and an intensity level
of 2+ as cut-off criteria. In our study, 68.4% (91/133) of
lung adenocarcinomas were EGFR IHC-positive accord-
ing to our interpreting criteria. EGFR protein expression
was significantly associated with EGFR copy number
and EGFR mutation, but not associated with gender,
age, smoking status, lymph node metastasis or stage.
The results suggest that EGFR protein expression may
predict EGFR gene status (including copy number and
mutation) to some extent. However, the patients positive
for the three EGFR markers did not completely overlap;
a proportion of FISH-positive and mutant samples was
IHC-negative. Thus, the mechanism needs to be clari-
fied in the future.
Conclusion
EGFR protein expression, EGFR copy number and
mutations were investigated in this study. Our results
revealed that the deletion in exon 19 and the L858R
point mutation were the major EGFR mutations in lung
adenocarcinomas, and EGFR mutations were signifi-
cantly associated with smoking status. Furthermore,
EGFR copy number was significantly associated with
EGFR mutation, and EGFR protein expression was sig-
nificantly correlated with EGFR copy number and muta-
tion. Standard methods and criteria should be
established for patient selection for EGFR target therapy.
Further studies will be required to determine whether
EGFR copy number and EGFR protein expression analy-
sis are suitable for individualized EGFR targeted therapy.
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